Table 1.

In vitro activities (MICs) of marinopyrrole A compared to those of commonly used antibiotics against selected clinical drug-resistant strains

StrainClassificationMIC (μg/ml)
Marinopyrrole AVancomycinLinezolid
Staphylococcus aureus
    ATCC 29213MSSA0.5–11–2NAb
    UAMS1 (USA200)MSSA0.751.5NA
    TCH1516 (USA300)CA-MRSA0.188–0.37523
    UAMS1182 (USA300)CA-MRSA0.188–0.3751.563
    NRS386 (USA700)CA/HA-MRSA0.3752–43
    Sanger 252HA-MRSA0.3751–23
    MRSA ATCC 33591HA-MRSA0.188–0.3751.56NA
    VRSA (Michigan)VRSA0.375–1.5>256NA
    VRSA (Pennsylvania)VRSA0.375–1>256NA
    A5940aHetero-GISA0.25–0.54NA
    PC-3 (New York)aVISA0.25–0.58NA
    HIP5836 (New Jersey)aVISA0.25–0.54-8NA
Other
    E. faecalisvanB1
    S. pyogenesGAS (MI-5548)1
    S. pyogenesGAS (M49-NZ131)1
    S. agalactiaeGBS (COHI)2
    S. epidermidisATCC 122280.25–1
    B. anthracisSterne strain1–2
    B. subtilisStrain 36100.94–1.87
    H. influenzaeATCC 10212
    K. pneumoniaeATCC 700603>16
    P. aeruginosaATCC 27853>96
    E. coliATCC 25922>120
  • a Reference 17.

  • b NA, not applicable.